Clinical Trial Update: SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial evaluating SupCD7 CAR T-cell therapy for relapsed or refractory CD7-positive hematologic malignancies is currently recruiting i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• T-cell Acute Lymphoblastic Leukemia
• T-cell Lymphoblastic Lymphoma

Drugs mentioned

• SupCD7 CAR T

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: T Lymphoblastic Leukemia/Lymphoma, Acute Myeloid Leukemia (AML) | Phase 1, Phase 2 | Status: RECRUITING